Literature DB >> 22617326

Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Ludmila Szabova1, Chaoying Yin, Sujata Bupp, Theresa M Guerin, Jerome J Schlomer, Deborah B Householder, Maureen L Baran, Ming Yi, Yurong Song, Wenping Sun, Jonathan E McDunn, Philip L Martin, Terry Van Dyke, Simone Difilippantonio.   

Abstract

The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617326      PMCID: PMC3421072          DOI: 10.1158/0008-5472.CAN-11-3834

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Authors:  Amy Finch; Mario Beiner; Jan Lubinski; Henry T Lynch; Pal Moller; Barry Rosen; Joan Murphy; Parviz Ghadirian; Eitan Friedman; William D Foulkes; Charmaine Kim-Sing; Teresa Wagner; Nadine Tung; Fergus Couch; Dominique Stoppa-Lyonnet; Peter Ainsworth; Mary Daly; Babara Pasini; Ruth Gershoni-Baruch; Charis Eng; Olufunmilayo I Olopade; Jane McLennan; Beth Karlan; Jeffrey Weitzel; Ping Sun; Steven A Narod
Journal:  JAMA       Date:  2006-07-12       Impact factor: 56.272

2.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

3.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.

Authors:  Deyin Xing; Sandra Orsulic
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

6.  Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.

Authors:  Katherine V Clark-Knowles; Kenneth Garson; Jos Jonkers; Barbara C Vanderhyden
Journal:  Exp Cell Res       Date:  2006-10-03       Impact factor: 3.905

7.  The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras.

Authors:  V M Ho; B E Schaffer; A N Karnezis; K S Park; J Sage
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

8.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Authors:  David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

9.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Authors:  Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

10.  Distant metastases in ovarian carcinoma.

Authors:  G Cormio; C Rossi; A Cazzolla; L Resta; G Loverro; P Greco; L Selvaggi
Journal:  Int J Gynecol Cancer       Date:  2003 Mar-Apr       Impact factor: 3.437

View more
  63 in total

1.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

Review 2.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

3.  Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer.

Authors:  Pradeep S Tanwar; Gayatry Mohapatra; Sarah Chiang; David A Engler; Lihua Zhang; Tomoko Kaneko-Tarui; Yasuyo Ohguchi; Michael J Birrer; Jose M Teixeira
Journal:  Carcinogenesis       Date:  2013-10-29       Impact factor: 4.944

4.  High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.

Authors:  Yali Zhai; Rong Wu; Rork Kuick; Michael S Sessine; Stephanie Schulman; Megan Green; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2017-07-25       Impact factor: 7.996

Review 5.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

6.  Mutant p53 expression in fallopian tube epithelium drives cell migration.

Authors:  Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

7.  Docosahexaenoic acid (DHA), an omega-3 fatty acid, inhibits tumor growth and metastatic potential of ovarian cancer.

Authors:  Lindsay West; Yajie Yin; Stuart R Pierce; Ziwei Fang; Yali Fan; Wenchuan Sun; Katherine Tucker; Allison Staley; Chunxiao Zhou; Victoria Bae-Jump
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

8.  Downregulation of B-myb promotes senescence via the ROS-mediated p53/p21 pathway, in vascular endothelial cells.

Authors:  Zhihui Zhou; Yanlin Yin; Qun Chang; Guanqun Sun; Jiahui Lin; Yalei Dai
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

9.  A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Authors:  Cheryl A Sherman-Baust; Elisabetta Kuhn; Blanca L Valle; Ie-Ming Shih; Robert J Kurman; Tian-Li Wang; Tomokazu Amano; Minoru S H Ko; Ichiro Miyoshi; Yoshihiko Araki; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Patrice J Morin
Journal:  J Pathol       Date:  2014-07       Impact factor: 7.996

10.  Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.

Authors:  Zoë Weaver; Simone Difilippantonio; Julian Carretero; Philip L Martin; Rajaa El Meskini; Anthony J Iacovelli; Michelle Gumprecht; Alan Kulaga; Theresa Guerin; Jerome Schlomer; Maureen Baran; Serguei Kozlov; Thomas McCann; Salvador Mena; Fatima Al-Shahrour; Danny Alexander; Kwok-Kin Wong; Terry Van Dyke
Journal:  Cancer Res       Date:  2012-09-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.